Diffuse large B-cell lymphoma (DLBCL) is the malignancy of the blood system, accounting for approximately 24-30% of Non-Hodgkin’s lymphoma (NHL).1 Primary breast lymphoma is extremely rare, accounting for approximately 0.5% malignancies of the breast and 1% of all NHL patients.2 Insulin resistance (IR) meas the inefficiency of insulin in promoting glucose ingestion and utilization. The gene discussed is INS; the disease is diffuse large B-cell lymphoma.